TY - JOUR AU - Ling, Wentong AU - Chen, Qiong AU - Huang, Pu AU - Han, Dengke AU - Wu, Wenjun PY - 2020/07/02 Y2 - 2024/03/29 TI - Impact of Glycosylated Hemoglobin on the Prognosis of Patients with Acute Ischemic Stroke Treated with Arterial Thrombolysis JF - The Heart Surgery Forum JA - HSF VL - 23 IS - 4 SE - DO - 10.1532/hsf.2929 UR - https://journal.hsforum.com/index.php/HSF/article/view/2929 SP - E447-E451 AB - <p class="p1"><span class="s1"><strong>Background:</strong> To investigate the impact of glycosylated hemoglobin (HbA1c) on the prognosis of patients with acute ischemic stroke (AIS) treated with intra-arterial thrombolysis (IAT).</span></p><p class="p1"><span class="s1"><strong>Methods:</strong> The clinical data of 136 patients with AIS treated with IAT at the Zhongshan City People’s Hospital were retrospectively analyzed. The patients were divided into a high HbA1c group (HHbA1c) (</span><span class="s2">≥</span><span class="s1">6.5%) and a normal HbA1c group (NHbA1c) (&lt;6.5%). According to National Institutes of Health Stroke Scale (NIHSS) score after thrombolysis, patients were divided into a good prognosis group (GP) (</span><span class="s2">≥</span><span class="s1">4 or &lt;4 points reduction) and a poor prognosis group (PP) (</span><span class="s2">≤</span><span class="s1">4 or &gt;4 points reduction).</span></p><p class="p1"><span class="s1"><strong>Results:</strong> There were significant differences in the HbA1c and glucose levels, NIHSS scores at admission and at discharge, complication rates, and mortality rates between groups HHbA1c and NHbA1c (<em>P</em> &lt; .05) and between groups GP and PP (<em>P</em> &lt; .05). The multivariate logistic regression analysis showed that HbA1c level (odds ratio [OR] 0.717; 95% confidence interval [CI] 0.545 to 0.889) and NIHSS score at admission (OR 0.894; 95% CI 0.814 to 0.982) were risk factors for neurological improvement in IAT-treated patients with AIS.</span></p><p class="p1"><span class="s1"><strong>Conclusions:</strong> HbA1c level is associated with neurological function improvement in IAT-treated patients with AIS and can be used as a serological indicator of poor prognosis.</span></p> ER -